07.11.16
Amgen has received FDA approval for a single, monthly 420 mg dose delivery option for Repatha (evolocumab), using West Pharmaceutical Services’ SmartDose technology.
"West is very pleased that Amgen has selected the SmartDose technology platform for the new monthly single dose administration option of Repatha," said Eric M. Green, president and chief executive officer, West. "The combination of Amgen's innovative treatment with West's patient-focused technology platform is an example of how West closely collaborates with our pharmaceutical and biotechnology partners to deliver advanced, integrated solutions for drug delivery and containment."
The SmartDose technology allows patients to self-administer medication via a platform that adheres to the patient's body, usually on the abdomen, for hands free administration. The SmartDose technology platform is an integrated solution of delivery and containment featuring a silicone-free Daikyo Crystal Zenith cartridge and a Flurotec coated piston containment system.
"West is very pleased that Amgen has selected the SmartDose technology platform for the new monthly single dose administration option of Repatha," said Eric M. Green, president and chief executive officer, West. "The combination of Amgen's innovative treatment with West's patient-focused technology platform is an example of how West closely collaborates with our pharmaceutical and biotechnology partners to deliver advanced, integrated solutions for drug delivery and containment."
The SmartDose technology allows patients to self-administer medication via a platform that adheres to the patient's body, usually on the abdomen, for hands free administration. The SmartDose technology platform is an integrated solution of delivery and containment featuring a silicone-free Daikyo Crystal Zenith cartridge and a Flurotec coated piston containment system.